![]() ![]() Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)Ĭalendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.Ĭryptocurrencies: Cryptocurrency quotes are updated in real-time. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv. Data may be intentionally delayed pursuant to supplier requirements. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Source: FactSetĭata are provided 'as is' for informational purposes only and are not intended for trading purposes. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Sources: FactSet, Tullett PrebonĬommodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Sources: FactSet, Tullett PrebonĬurrencies: Currency quotes are updated in real-time. Sources: FactSet, Dow Jonesīonds: Bond quotes are updated in real-time. Sources: FactSet, Dow JonesĮTF Movers: Includes ETFs & ETNs with volume of at least 50,000. Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Overview page represent trading in all U.S. Indexes: Index quotes may be real-time or delayed as per exchange requirements refer to time stamps for information on any delays. Copyright © FactSet Research Systems Inc. Fundamental company data and analyst estimates provided by FactSet. International stock quotes are delayed as per exchange requirements. stock quotes reflect trades reported through Nasdaq only comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Our employee-led Diversity efforts are inspired by our guiding principles to focus awareness on social equity and create positive change not only within 4DMT, but in our community at large. at $8.04 per shareĭerivative/Non-derivative trans. 4DMT champions diversity, equity and inclusion every single day. at $6.49 per shareĭerivative/Non-derivative trans. Bizily Chief Legal and HR Officerĭerivative/Non-derivative trans. Several AAV gene therapy products are in late-stage clinical development, and one product is approved in the EU (Glybera, Uniqure).David H. They can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. Adeno-associated virus (AAV) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. A large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4D products.ĤD has one of the deepest and most diverse product pipelines in the gene therapy field. Our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. The company designs, develops and commercializes transformative gene therapeutic products for. The mission of 4D Molecular Therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. Emeryville, California Type Public Company Founded 2013 Specialties Gene Therapy, Adeno-Associated Virus, Biotechnology, Rare Diseases, Clinical, Lab, Clinical Trials, and Science Locations. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |